KRAS and pancreatic neoplasm: Therefore, we examined a new transgenic pancreatic cancer model called KDC (PdxCre+KRasLSL‐G12D/+dusp6−/−), whose mice possess the same activating mutation in KRas as KPC mice together with deletion of the dual‐specificity phosphatase 6 (dusp6) targeted to the pancreas.